Dhuwit awis perusahaan: primemedicine.com (PRME)

Tandha merek Prime Medicine (PRME)

Prime Medicine, Inc. (PRME) is considered a medical visionary due to its innovative approach to DNA editing. The company is developing universal therapy methods for hereditary pathologies, leveraging proprietary precision editing and support from Big Pharma. The current cash position illustrates the asset's financial stability, while 0.06 characterizes this valuation parameter, helping to determine the balance between liquidity and capital efficiency.

PRME - Aset likuid perusahaan Prime Medicine Corp ing rentang 28.04.2023 - 21.11.2026

Rincian metrik lan analitis perusahaan Prime Medicine Corp (PRME)

Analisis dhasar perusahaan:PRME Prime Medicine Corp
Produk merek Prime Medicine Inc

Prime Medicine, Inc. (PRME) leadership in precision DNA editing and its robust patent portfolio require colossal R&D investments to monetize these technologies. By analyzing the cash balance history, an investor assesses the burn rate: while excess liquidity confirms solvency, stagnation or excessive growth may indicate inefficient resource management and a decline in future business profitability.

Analisis pesaing Prime Medicine, Inc.

Volume dana dhuwit perusahaan TEM|QGEN - Cadangan dhuwit perusahaan|ionispharma.com - Dhuwit awis perusahaan|Sisa dhuwit perusahaan RGEN|Avidity Corp - Volume dana dhuwit perusahaan|CRISPR Therapeutics Corp - Gunggung dana dhuwit perusahaan|GeneDx Holdings (WGS) - Dana dhuwit perusahaan|Ultragenyx Pharmaceutical (RARE) - Volume dana dhuwit perusahaan|Dhuwit awis perusahaan BEAM|Sarepta (SRPT) - Aset likuid perusahaan|Dana dhuwit perusahaan Twist Bioscience Corp (TWST)|10x - Dhuwit awis lan setara dhuwit awis perusahaan|Volume dana dhuwit perusahaan NTLA (intelliatx.com)|Gunggung dana dhuwit perusahaan STOK (stoketherapeutics.com)|BioLife Solutions Inc - Volume dana dhuwit perusahaan|WVE (Wave Life Sciences Ltd) - Dhuwit awis lan setara dhuwit awis perusahaan|Maze Therapeutics Corp (MAZE) - Dana dhuwit perusahaan|Dhuwit awis lan setara dhuwit awis perusahaan SION|Dana dhuwit perusahaan tayshagtx.com|QURE - Posisi dhuwit perusahaan|Dhuwit awis perusahaan MGTX (MeiraGTx Holdings plc)|REGENXBIO (RGNX) - Posisi dhuwit perusahaan|Volume dana dhuwit perusahaan SLDB (Solid Biosciences Inc.)|Sisa dhuwit perusahaan OCGN|PacBio Corp - Volume dana dhuwit perusahaan|Benitec Biopharma Inc. (BNTC) - Dhuwit awis perusahaan|DSGN: Volume dana dhuwit perusahaan|Dhuwit awis lan setara dhuwit awis perusahaan RCKT|Dhuwit awis perusahaan FDMT|Dhuwit awis lan setara dhuwit awis perusahaan LXEO (Lexeo Therapeutics)|Volume dana dhuwit perusahaan KRRO|Editas Medicine, Inc. - Dhuwit awis lan setara dhuwit awis perusahaan|Dana dhuwit perusahaan Silence Therapeutics Inc. SLN|Volume dana dhuwit perusahaan ProQR Therapeutics N.V. PRQR|CDXS: Dhuwit awis perusahaan|Posisi dhuwit perusahaan Sangamo (SGMO)|NAUT (Nautilus Bio) - Dhuwit awis perusahaan|MGX - Aset likuid perusahaan|DTIL (Precision BioSciences Inc.) - Volume dana dhuwit perusahaan|generationbio.com (GBIO) - Aset likuid perusahaan|Dana dhuwit perusahaan Boundless Bio Inc (BOLD)|Volume dana dhuwit perusahaan Exicure Inc. (XCUR)|Dana dhuwit perusahaan imunon.com IMNN|Volume dana dhuwit perusahaan Phio Pharmaceuticals PHIO|Mustang Bio Inc - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan transcodetherapeutics.com|BNGO: Volume dana dhuwit perusahaan|Dhuwit awis lan setara dhuwit awis perusahaan APDN|BLUE (bluebirdbio.com) - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan ImmunoPrecise Antibodies IPA|Dhuwit awis perusahaan OMGA (omegatherapeutics.com)|Volume dana dhuwit perusahaan Singular Genomics Systems, Inc. (OMIC)|Volume dana dhuwit perusahaan RGLS (Regulus Therapeutics, Inc.)|Volume dana dhuwit perusahaan Syros SYRS|Telesis Bio, Inc. - Volume dana dhuwit perusahaan|TRACON Pharmaceuticals (TCON) - Dhuwit awis perusahaan|UBX: Volume dana dhuwit perusahaan